Keywords: vertex, stock, soars, positive, phase, ib, data
Vertex stock soars on positive Phase Ib data for hepatitis C drug VX-950
Article | 16 May 2005
Vertex Pharmaceuticals' Nasdaq-traded stock leapt 19.8% to close at $13.40 on May 10, as investor excitement was ignited by positive interim results demonstrating ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
